CDC Advisory Committee Recommends Preferential Use of Live Attenuated Influenza Vaccine (LAIV) for Eligible Children 2 to 8 Years of Age

June 26, 2014 The MedImmune Specialty Care division of AstraZeneca announced that the U.S. Centers for Disease Control & Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that when available, Live Attenuated Influenza Vaccine (LAIV) should be used for healthy children 2 to 8 years of age, who have no contraindications or precautions. The ACIP’s unanimous vote was based on …

Vaccine

Presentation: Live attenuated influenza vaccine and its clinical development in China

At the last Influenza Summit, part of World Vaccine Congress Asia, Prof.Dr. Xu Fei of Changchun BCHT Biotechnology Co. gave the following presentation entitled: Live attenuated influenza vaccine (LAIV) and its clinical development in China. Some points discussed during the presentation include: BCHT overview LAIV introduction Review of Clinical Data Development of clinical trial strategy in China Download the presentation …